Comparing the current results to its competitors, Altimmune Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 6.93 %, recorded in the same quarter.
Altimmune inc , slower than the average decrease reported by the company's competitors of -28.22 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -28.22 %
Altimmune Inc 's Comment on Competition and Industry Peers
The biopharmaceutical industry is characterized by competition based on product efficacy, safety, reliability, availability, price, patent position, and timing of market introduction. Success in this industry depends on rapid product development, clinical trials, regulatory approvals, manufacturing, and market supply. Competitive advantages include product differentiation, qualified personnel, patent protection, proprietary products or processes, and sufficient capital. Large, established companies with extensive resources and experience operate in the same therapeutic areas, often possessing approved products or late-stage developments and collaborations in target markets. Competitors identified in filings include Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, Pfizer, and Roche.
September 21, 2025
The pharmaceutical industry is a dynamic and competitive arena, with significant implications for investors and stakeholders. Altimmune, Inc. (NASDAQ: ALT), a notable entity within this sector, has recently come under scrutiny due to a combination of legal concerns and stagnant revenue performance. This article explores these challenges in detail, sheds light on their implications, and provides context by comparing Altimmune s market performance with its competitors. Legal Developments: The Securities Class Action Altimmune, Inc. is currently entangled in a securities class action lawsuit, spearheaded by the renowned Rosen Law Firm. The firm, recognized for its leadership in protecting investor rights global...
September 30, 2024
In an announcement poised to stir considerable interest within the scientific and financial communities, Altimmune Inc. a nascent titan in the realm of biopharmaceuticals, hath proclaimed the successful completion of subject enrollment for its esteemed Phase 2b IMPACT trial. This significant clinical endeavour seeks to evaluate the safety and efficacy of pemvidutide, a novel therapeutic agent, in the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), afflicting a notable populace burdened with metabolic ailments.The IMPACT trial aims to encompass approximately one hundred and ninety participants diagnosed with MASH, thereby seeking to elucidate the potential of pemvidutide as a viable inte...
September 3, 2024
Altimmune Presents Promising Pemvidutide Data at EASD Annual Meeting: A Breakthrough in Obesity and MASH TreatmentAltimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, has garnered significant attention with its recent announcement. The compelling clinical data from its Phase 2 MRI-based body composition sub-study of pemvidutide will be shared at the prestigious 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain. This development underscores Altimmune’s commitment to advancing innovative treatments for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Understanding Pemvidutide Pemvidutide is a novel, investigational pept...
Xbiotech Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic antibodies. They seek to address unmet medical needs by leveraging their proprietary True Human antibody technology.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Opko Health Inc is a biotechnology and pharmaceutical company that operates through various business segments. The company primarily focuses on diagnostics, developing and commercializing novel diagnostic tests for various conditions. Additionally, Opko Health engages in the production and sale of pharmaceuticals and vaccines, as well as the research and development of new medical technologies.
Sources:
Altimmune inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Altimmune inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
